TokenPost·
FDA Clears Alvotech Process to More Than Double Simlandi Drug Substance Output
The process applies to Alvotech’s DSM2 manufacturing suite in Reykjavik, Iceland, which was previously cleared to supply drug substance for the U.S. market.
More news
- TokenPostSEC and Japan’s FSA Discuss Market Developments in Tokyo
- TokenPostBitfinex Receives 100.98 Million USDT From Unidentified Wallet
- Crypto BriefingSpaceX revenue jumps 161% to $14.6B as AI business surges in third quarter
- Crypto BriefingSpaceX posts $4.4B quarterly profit as AI revenue overtakes rockets
- TokenPostTrinity Capital Commits $20 Million to ABM Respiratory Care
- Crypto BriefingIonic faces a possible activist push for board seats as its AI pivot takes shape